Breaking News, Financial News

Financial Reports: GlaxoSmithKline

Loss of Vesicare revenues hurts U.S. results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 1Q13* 1Q Revenues: £6.5 billion (-2%) 1Q: Earnings: £1.5 billion (-24%) Comments: Combined pharmaceuticals and vaccines sales were down 2% (£5.1 billion), including a 6% drop in the U.S (£1.7 billion), -3% in Europe (£1.3 billion), and -6% in Japan (£447 million). Pharma sales worldwide were £4.4 billion (-1%) while vaccines fell 11% to £680 million. The respiratory franchise grew 6% to £1.9 billion, with Advair sales of £1.3 billion (+4%) and Flovent sales +7% to £213 million...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters